Cabozantinib

Overview

Cabozantinib is a c-Met inhibitor that is currently FDA approved for the treatment of patients with advanced renal cell carcinoma (RCC).

SparkCures ID 69
Developed By Exelixis
Generic Name Cabozantinib
Additional Names Cabometyx
Treatment Classifications
  • Bruton's Tyrosine Kinase (BTK) Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.